Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Venous Thrombosis 1Venous Thromboembolism 1Vascular Diseases 1Urogenital Neoplasms 1Thromboembolism 1Prostatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma 1Lymphatic Diseases 1Lung Neoplasms 1Leukemia 1Intestinal Neoplasms 1Hemostatic Disorders 1Digestive System Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Azacitidine 68nilotinib 50Imatinib Mesylate 50ruxolitinib 42Dasatinib 25venetoclax 22Decitabine 20bosutinib 18asciminib 17Cytarabine 15ponatinib 10decitabine and cedazuridine drug combination 10AP 1903 reagent 10Cyclophosphamide 9fludarabine 8Hydroxyurea 8navitoclax 6ON 01910 6sabatolimab 5pevonedistat 5mocetinostat 5luspatercept 5itacitinib 5imetelstat 5givinostat hydrochloride 5givinostat 5fludarabine phosphate 5avapritinib 5Mycophenolic Acid 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Tinzaparin × Myeloid × Clear all
NCT03099031 2019-12-16

PREDICARE

LEO Pharma

Completed
420 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Digestive System Neoplasms, Intestinal Neoplasms, Leukemia, Lung Neoplasms, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Myeloproliferative Disorders, Neoplasms, Prostatic Neoplasms, Thromboembolism, Urogenital Neoplasms, Vascular Diseases, Colorectal Neoplasms, Hemostatic Disorders, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡